Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
ARrest RESpiraTory Failure From PNEUMONIA
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Inhaled budesonide and formoterol
- drug: Inhaled placebo
Eligibility
Inclusion Criteria:
Patients 18 years or older with
Severe pneumonia defined as:
1. Hospitalization for acute (defined as ≤ 14 days) onset of symptoms (cough, sputum
production, or dyspnea), AND 2. Radiographic evidence of pneumonia by chest radiograph or
CT scan, AND 3. One of the following:
1. Evidence of systemic inflammation (temperature < 35◦C or > 38◦C OR WBC > or < upper or
lower limits for site OR procalcitonin > 0.5 mcg/L), OR
2. Known current immunosuppression preventing inflammatory response, OR
3. High clinical suspicion of pneumonia with microbiologic confirmation of infection.
Microbiologic confirmation will include a positive nasal swab for a known respiratory
virus; a sputum culture growing a likely pathogenic organism plus moderate or greater
WBCs (not required for immunocompromised patients); or a positive blood culture with a
likely pathogenic organism - e.g., ¼ vials with S. Epidermidis would NOT qualify)
AND Hypoxemia defined as new requirement for daytime supplemental oxygen with SpO2 < 92% on
room air, ≤ 96% on ≥ 2 L/min oxygen, or > 6L/min or non-invasive ventilation regardless of
SpO2 at enrollment. Patients admitted with pneumonia but not meeting criteria for hypoxemia
will be followed for up to 24 hours from ED admission to enrolling hospital to assess for
development of qualifying hypoxemia.
Exclusion Criteria:
- Inability to obtain consent within 24 hours of presentation to enrolling hospital (up
to 12 hours allowed at transferring ED for maximum of 36 hours from presentation)
- Intubation (or impending intubation) prior to enrollment
a. Patients receiving HFNC oxygen or NIV prior to enrollment are not excluded
- A condition requiring inhaled corticosteroids or beta-agonists (patients receiving
inhaled beta-agonists in the ED without an established indication will be eligible if
treating clinician is willing to discontinue subsequent treatments)
- Chronic systemic steroid therapy equivalent to >10 mg prednisone
- COVID-19 positive patients receiving > 6 mg dexamethasone (40 mg prednisone equivalent
dose) except for stress dose steroids for septic shock
- Non-COVID-19 pneumonia patients receiving systemic steroid > 10 mg prednisone except
for stress dose steroids for septic shock
- Chronic lung or neuromuscular disease requiring daytime oxygen or mechanical
ventilation other than for obstructive sleep apnea (OSA) or obesity hypoventilation
syndrome
- Not anticipated to survive > 48 hours or not expected to require > 48 hours of
hospitalization
- Contraindication or allergy to inhaled corticosteroids or beta-agonists
- Patients with heart rate > 130 bpm, ventricular tachycardia or new supraventricular
tachycardia within last 4 hours will be potentially eligible for enrollment after the
condition has resolved
- Patients with K+ < 3.0 will be potentially eligible for enrollment after the condition
has resolved
- Patient not committed to full support other than intubation or resuscitation (i.e.,
DNR/DNI status allowed)
- Pregnancy
- Incarcerated individual
- Physician refusal of consent to protocol
- Patient/surrogate refusal of consent to protocol
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joe Levitt, MD
650-723-6381
I'm interested
Psoriasis Clinical Trials
ARrest RESpiraTory Failure From PNEUMONIA
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Inhaled budesonide and formoterol
- drug: Inhaled placebo
Eligibility
Inclusion Criteria:
Patients 18 years or older with
Severe pneumonia defined as:
1. Hospitalization for acute (defined as ≤ 14 days) onset of symptoms (cough, sputum
production, or dyspnea), AND 2. Radiographic evidence of pneumonia by chest radiograph or
CT scan, AND 3. One of the following:
1. Evidence of systemic inflammation (temperature < 35◦C or > 38◦C OR WBC > or < upper or
lower limits for site OR procalcitonin > 0.5 mcg/L), OR
2. Known current immunosuppression preventing inflammatory response, OR
3. High clinical suspicion of pneumonia with microbiologic confirmation of infection.
Microbiologic confirmation will include a positive nasal swab for a known respiratory
virus; a sputum culture growing a likely pathogenic organism plus moderate or greater
WBCs (not required for immunocompromised patients); or a positive blood culture with a
likely pathogenic organism - e.g., ¼ vials with S. Epidermidis would NOT qualify)
AND Hypoxemia defined as new requirement for daytime supplemental oxygen with SpO2 < 92% on
room air, ≤ 96% on ≥ 2 L/min oxygen, or > 6L/min or non-invasive ventilation regardless of
SpO2 at enrollment. Patients admitted with pneumonia but not meeting criteria for hypoxemia
will be followed for up to 24 hours from ED admission to enrolling hospital to assess for
development of qualifying hypoxemia.
Exclusion Criteria:
- Inability to obtain consent within 24 hours of presentation to enrolling hospital (up
to 12 hours allowed at transferring ED for maximum of 36 hours from presentation)
- Intubation (or impending intubation) prior to enrollment
a. Patients receiving HFNC oxygen or NIV prior to enrollment are not excluded
- A condition requiring inhaled corticosteroids or beta-agonists (patients receiving
inhaled beta-agonists in the ED without an established indication will be eligible if
treating clinician is willing to discontinue subsequent treatments)
- Chronic systemic steroid therapy equivalent to >10 mg prednisone
- COVID-19 positive patients receiving > 6 mg dexamethasone (40 mg prednisone equivalent
dose) except for stress dose steroids for septic shock
- Non-COVID-19 pneumonia patients receiving systemic steroid > 10 mg prednisone except
for stress dose steroids for septic shock
- Chronic lung or neuromuscular disease requiring daytime oxygen or mechanical
ventilation other than for obstructive sleep apnea (OSA) or obesity hypoventilation
syndrome
- Not anticipated to survive > 48 hours or not expected to require > 48 hours of
hospitalization
- Contraindication or allergy to inhaled corticosteroids or beta-agonists
- Patients with heart rate > 130 bpm, ventricular tachycardia or new supraventricular
tachycardia within last 4 hours will be potentially eligible for enrollment after the
condition has resolved
- Patients with K+ < 3.0 will be potentially eligible for enrollment after the condition
has resolved
- Patient not committed to full support other than intubation or resuscitation (i.e.,
DNR/DNI status allowed)
- Pregnancy
- Incarcerated individual
- Physician refusal of consent to protocol
- Patient/surrogate refusal of consent to protocol
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joe Levitt, MD
650-723-6381
I'm interested
Dermatology Clinical Trials
ARrest RESpiraTory Failure From PNEUMONIA
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Inhaled budesonide and formoterol
- drug: Inhaled placebo
Eligibility
Inclusion Criteria:
Patients 18 years or older with
Severe pneumonia defined as:
1. Hospitalization for acute (defined as ≤ 14 days) onset of symptoms (cough, sputum
production, or dyspnea), AND 2. Radiographic evidence of pneumonia by chest radiograph or
CT scan, AND 3. One of the following:
1. Evidence of systemic inflammation (temperature < 35◦C or > 38◦C OR WBC > or < upper or
lower limits for site OR procalcitonin > 0.5 mcg/L), OR
2. Known current immunosuppression preventing inflammatory response, OR
3. High clinical suspicion of pneumonia with microbiologic confirmation of infection.
Microbiologic confirmation will include a positive nasal swab for a known respiratory
virus; a sputum culture growing a likely pathogenic organism plus moderate or greater
WBCs (not required for immunocompromised patients); or a positive blood culture with a
likely pathogenic organism - e.g., ¼ vials with S. Epidermidis would NOT qualify)
AND Hypoxemia defined as new requirement for daytime supplemental oxygen with SpO2 < 92% on
room air, ≤ 96% on ≥ 2 L/min oxygen, or > 6L/min or non-invasive ventilation regardless of
SpO2 at enrollment. Patients admitted with pneumonia but not meeting criteria for hypoxemia
will be followed for up to 24 hours from ED admission to enrolling hospital to assess for
development of qualifying hypoxemia.
Exclusion Criteria:
- Inability to obtain consent within 24 hours of presentation to enrolling hospital (up
to 12 hours allowed at transferring ED for maximum of 36 hours from presentation)
- Intubation (or impending intubation) prior to enrollment
a. Patients receiving HFNC oxygen or NIV prior to enrollment are not excluded
- A condition requiring inhaled corticosteroids or beta-agonists (patients receiving
inhaled beta-agonists in the ED without an established indication will be eligible if
treating clinician is willing to discontinue subsequent treatments)
- Chronic systemic steroid therapy equivalent to >10 mg prednisone
- COVID-19 positive patients receiving > 6 mg dexamethasone (40 mg prednisone equivalent
dose) except for stress dose steroids for septic shock
- Non-COVID-19 pneumonia patients receiving systemic steroid > 10 mg prednisone except
for stress dose steroids for septic shock
- Chronic lung or neuromuscular disease requiring daytime oxygen or mechanical
ventilation other than for obstructive sleep apnea (OSA) or obesity hypoventilation
syndrome
- Not anticipated to survive > 48 hours or not expected to require > 48 hours of
hospitalization
- Contraindication or allergy to inhaled corticosteroids or beta-agonists
- Patients with heart rate > 130 bpm, ventricular tachycardia or new supraventricular
tachycardia within last 4 hours will be potentially eligible for enrollment after the
condition has resolved
- Patients with K+ < 3.0 will be potentially eligible for enrollment after the condition
has resolved
- Patient not committed to full support other than intubation or resuscitation (i.e.,
DNR/DNI status allowed)
- Pregnancy
- Incarcerated individual
- Physician refusal of consent to protocol
- Patient/surrogate refusal of consent to protocol
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joe Levitt, MD
650-723-6381
I'm interested
Pediatric Dermatology Clinical Trials
ARrest RESpiraTory Failure From PNEUMONIA
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Inhaled budesonide and formoterol
- drug: Inhaled placebo
Eligibility
Inclusion Criteria:
Patients 18 years or older with
Severe pneumonia defined as:
1. Hospitalization for acute (defined as ≤ 14 days) onset of symptoms (cough, sputum
production, or dyspnea), AND 2. Radiographic evidence of pneumonia by chest radiograph or
CT scan, AND 3. One of the following:
1. Evidence of systemic inflammation (temperature < 35◦C or > 38◦C OR WBC > or < upper or
lower limits for site OR procalcitonin > 0.5 mcg/L), OR
2. Known current immunosuppression preventing inflammatory response, OR
3. High clinical suspicion of pneumonia with microbiologic confirmation of infection.
Microbiologic confirmation will include a positive nasal swab for a known respiratory
virus; a sputum culture growing a likely pathogenic organism plus moderate or greater
WBCs (not required for immunocompromised patients); or a positive blood culture with a
likely pathogenic organism - e.g., ¼ vials with S. Epidermidis would NOT qualify)
AND Hypoxemia defined as new requirement for daytime supplemental oxygen with SpO2 < 92% on
room air, ≤ 96% on ≥ 2 L/min oxygen, or > 6L/min or non-invasive ventilation regardless of
SpO2 at enrollment. Patients admitted with pneumonia but not meeting criteria for hypoxemia
will be followed for up to 24 hours from ED admission to enrolling hospital to assess for
development of qualifying hypoxemia.
Exclusion Criteria:
- Inability to obtain consent within 24 hours of presentation to enrolling hospital (up
to 12 hours allowed at transferring ED for maximum of 36 hours from presentation)
- Intubation (or impending intubation) prior to enrollment
a. Patients receiving HFNC oxygen or NIV prior to enrollment are not excluded
- A condition requiring inhaled corticosteroids or beta-agonists (patients receiving
inhaled beta-agonists in the ED without an established indication will be eligible if
treating clinician is willing to discontinue subsequent treatments)
- Chronic systemic steroid therapy equivalent to >10 mg prednisone
- COVID-19 positive patients receiving > 6 mg dexamethasone (40 mg prednisone equivalent
dose) except for stress dose steroids for septic shock
- Non-COVID-19 pneumonia patients receiving systemic steroid > 10 mg prednisone except
for stress dose steroids for septic shock
- Chronic lung or neuromuscular disease requiring daytime oxygen or mechanical
ventilation other than for obstructive sleep apnea (OSA) or obesity hypoventilation
syndrome
- Not anticipated to survive > 48 hours or not expected to require > 48 hours of
hospitalization
- Contraindication or allergy to inhaled corticosteroids or beta-agonists
- Patients with heart rate > 130 bpm, ventricular tachycardia or new supraventricular
tachycardia within last 4 hours will be potentially eligible for enrollment after the
condition has resolved
- Patients with K+ < 3.0 will be potentially eligible for enrollment after the condition
has resolved
- Patient not committed to full support other than intubation or resuscitation (i.e.,
DNR/DNI status allowed)
- Pregnancy
- Incarcerated individual
- Physician refusal of consent to protocol
- Patient/surrogate refusal of consent to protocol
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joe Levitt, MD
650-723-6381
I'm interested
ARrest RESpiraTory Failure From PNEUMONIA
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Inhaled budesonide and formoterol
- drug: Inhaled placebo
Eligibility
Inclusion Criteria:
Patients 18 years or older with
Severe pneumonia defined as:
1. Hospitalization for acute (defined as ≤ 14 days) onset of symptoms (cough, sputum
production, or dyspnea), AND 2. Radiographic evidence of pneumonia by chest radiograph or
CT scan, AND 3. One of the following:
1. Evidence of systemic inflammation (temperature < 35◦C or > 38◦C OR WBC > or < upper or
lower limits for site OR procalcitonin > 0.5 mcg/L), OR
2. Known current immunosuppression preventing inflammatory response, OR
3. High clinical suspicion of pneumonia with microbiologic confirmation of infection.
Microbiologic confirmation will include a positive nasal swab for a known respiratory
virus; a sputum culture growing a likely pathogenic organism plus moderate or greater
WBCs (not required for immunocompromised patients); or a positive blood culture with a
likely pathogenic organism - e.g., ¼ vials with S. Epidermidis would NOT qualify)
AND Hypoxemia defined as new requirement for daytime supplemental oxygen with SpO2 < 92% on
room air, ≤ 96% on ≥ 2 L/min oxygen, or > 6L/min or non-invasive ventilation regardless of
SpO2 at enrollment. Patients admitted with pneumonia but not meeting criteria for hypoxemia
will be followed for up to 24 hours from ED admission to enrolling hospital to assess for
development of qualifying hypoxemia.
Exclusion Criteria:
- Inability to obtain consent within 24 hours of presentation to enrolling hospital (up
to 12 hours allowed at transferring ED for maximum of 36 hours from presentation)
- Intubation (or impending intubation) prior to enrollment
a. Patients receiving HFNC oxygen or NIV prior to enrollment are not excluded
- A condition requiring inhaled corticosteroids or beta-agonists (patients receiving
inhaled beta-agonists in the ED without an established indication will be eligible if
treating clinician is willing to discontinue subsequent treatments)
- Chronic systemic steroid therapy equivalent to >10 mg prednisone
- COVID-19 positive patients receiving > 6 mg dexamethasone (40 mg prednisone equivalent
dose) except for stress dose steroids for septic shock
- Non-COVID-19 pneumonia patients receiving systemic steroid > 10 mg prednisone except
for stress dose steroids for septic shock
- Chronic lung or neuromuscular disease requiring daytime oxygen or mechanical
ventilation other than for obstructive sleep apnea (OSA) or obesity hypoventilation
syndrome
- Not anticipated to survive > 48 hours or not expected to require > 48 hours of
hospitalization
- Contraindication or allergy to inhaled corticosteroids or beta-agonists
- Patients with heart rate > 130 bpm, ventricular tachycardia or new supraventricular
tachycardia within last 4 hours will be potentially eligible for enrollment after the
condition has resolved
- Patients with K+ < 3.0 will be potentially eligible for enrollment after the condition
has resolved
- Patient not committed to full support other than intubation or resuscitation (i.e.,
DNR/DNI status allowed)
- Pregnancy
- Incarcerated individual
- Physician refusal of consent to protocol
- Patient/surrogate refusal of consent to protocol
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joe Levitt, MD
650-723-6381
I'm interested
ARrest RESpiraTory Failure From PNEUMONIA
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Inhaled budesonide and formoterol
- drug: Inhaled placebo
Eligibility
Inclusion Criteria:
Patients 18 years or older with
Severe pneumonia defined as:
1. Hospitalization for acute (defined as ≤ 14 days) onset of symptoms (cough, sputum
production, or dyspnea), AND 2. Radiographic evidence of pneumonia by chest radiograph or
CT scan, AND 3. One of the following:
1. Evidence of systemic inflammation (temperature < 35◦C or > 38◦C OR WBC > or < upper or
lower limits for site OR procalcitonin > 0.5 mcg/L), OR
2. Known current immunosuppression preventing inflammatory response, OR
3. High clinical suspicion of pneumonia with microbiologic confirmation of infection.
Microbiologic confirmation will include a positive nasal swab for a known respiratory
virus; a sputum culture growing a likely pathogenic organism plus moderate or greater
WBCs (not required for immunocompromised patients); or a positive blood culture with a
likely pathogenic organism - e.g., ¼ vials with S. Epidermidis would NOT qualify)
AND Hypoxemia defined as new requirement for daytime supplemental oxygen with SpO2 < 92% on
room air, ≤ 96% on ≥ 2 L/min oxygen, or > 6L/min or non-invasive ventilation regardless of
SpO2 at enrollment. Patients admitted with pneumonia but not meeting criteria for hypoxemia
will be followed for up to 24 hours from ED admission to enrolling hospital to assess for
development of qualifying hypoxemia.
Exclusion Criteria:
- Inability to obtain consent within 24 hours of presentation to enrolling hospital (up
to 12 hours allowed at transferring ED for maximum of 36 hours from presentation)
- Intubation (or impending intubation) prior to enrollment
a. Patients receiving HFNC oxygen or NIV prior to enrollment are not excluded
- A condition requiring inhaled corticosteroids or beta-agonists (patients receiving
inhaled beta-agonists in the ED without an established indication will be eligible if
treating clinician is willing to discontinue subsequent treatments)
- Chronic systemic steroid therapy equivalent to >10 mg prednisone
- COVID-19 positive patients receiving > 6 mg dexamethasone (40 mg prednisone equivalent
dose) except for stress dose steroids for septic shock
- Non-COVID-19 pneumonia patients receiving systemic steroid > 10 mg prednisone except
for stress dose steroids for septic shock
- Chronic lung or neuromuscular disease requiring daytime oxygen or mechanical
ventilation other than for obstructive sleep apnea (OSA) or obesity hypoventilation
syndrome
- Not anticipated to survive > 48 hours or not expected to require > 48 hours of
hospitalization
- Contraindication or allergy to inhaled corticosteroids or beta-agonists
- Patients with heart rate > 130 bpm, ventricular tachycardia or new supraventricular
tachycardia within last 4 hours will be potentially eligible for enrollment after the
condition has resolved
- Patients with K+ < 3.0 will be potentially eligible for enrollment after the condition
has resolved
- Patient not committed to full support other than intubation or resuscitation (i.e.,
DNR/DNI status allowed)
- Pregnancy
- Incarcerated individual
- Physician refusal of consent to protocol
- Patient/surrogate refusal of consent to protocol
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joe Levitt, MD
650-723-6381
I'm interested